People conducting clinical case studies
Work on clinical case studies is done by researchers from univeristies and industry together with patient organisations and HTA bodies.
Our patient and clinical research partners from the University of Newcastle upon Tyne, University of Birmingham, Istituto Tumori Bari, European Cancer Patients Coalition (ECPC),and Muscular Dystrophy UK (MDUK), play important roles by providing expertise on cancer, rheumatoid arthritis and neuromuscular disorders.
Ardine de Wit, public lead for case studies
Ardine de Wit is a specialist in Health Technology Assessment and health economics. She is an Associate Professor of HTA and head of the Department of HTA of the Julius Centre for Health Sciences and Primary Care (University Medical Centre Utrecht). Her research interests concern the economic evaluation of healthcare and prevention, as well as patient preferences. She has been involved in a large number of patient preference studies in the field of public health and healthcare. She is currently a member of the Scientific Advisory Council on reimbursement of medicines of the National Health Care Institute of the Netherlands.
Andrea Beyer, private lead for case studies
Andrea Beyer has a Master's degree in Public Health from Emory University and a PhD in Medical Sciences from University of Groningen. Andrea has worked in the field of Epidemiology, both in the US and in Europe, and was also a key member of the EMA Benefit-Risk Methodology project and led the IMI PROTECT-WP6 on the feasibility of extending benefit-risk methodologies to patients, healthcare professionals, and regulatory authorities. Her research areas of interest are measuring individual differences in risk attitude, risk perception, and benefit-risk trade-offs. Andrea Beyer is now a Senior Expert Statistician at Actelion Pharmaceuticals Ltd covering epidemiology/observational studies and patient centric study designs.
Jorien Veldwijk, public co-lead for case studies
Jorien Veldwijk is a postdoctoral researcher at Uppsala University’s Centre for Research Ethics & Bioethics (CRB). She is also a senior research fellow at the Erasmus Medical Center. Dr. Veldwijk’s research mainly covers measuring patients’ decision-making within a broad range of health care and public health topics as well as methodological issues. She is involved as a DCE expert in several studies in different organisations and countries, combining applied and methodological research which has resulted in publications in high-impact journals.
Leo Russo, private co-lead for case studies
Leo J. Russo, PhD is currently a Senior Director in Pfizer’s Worldwide Epidemiology Department. His academic training began in the field of statistics, in which he holds a Bachelor of Science degree from THE Ohio State University. Leo went on to complete his M.S. and PhD degrees in epidemiology at Case Western Reserve School of Medicine. Leo has been a practicing epidemiologist for over 20 years, of which the last 16 has been with the pharmaceutical industry. Leo is currently on the editorial board of the journal Therapeutic Advances in Drug Safety, and is a regular peer reviewer for the journal Pharmacoepidemiology and Drug Safety. He is a strong advocate for epidemiology and takes many opportunities to speak about the field and its power to advance health and drive innovation in the pharmaceutical industry. He is currently focusing on preparing Pfizer for a future of patient preference studies being an essential piece of a product’s benefit-risk profile.
Patient representatives in clincial case studies work
The patient representation in the PREFER clincial case studies is led by Muscular Dystrophy UK (MDUK), together with the European Cancer Patients Coalition (ECPC).
Jenny Sharpe, MDUK
Jenny Sharpe (MDUK) leads the patient input in the clinical case studies. She also gives input to PREFER communications, methodology and recommendations. Jenny is MDUK’s Research Communications Officer and is primarily responsible for translating research findings into a language that patients can understand. This involves engaging with a range of people, including scientists, industry representatives, clinicians, and individuals and families affected by neuromuscular conditions. Prior to joining MDUK, she completed a PhD in mitochondrial biology at University College London.
Francesco De Lorenzo, ECPC
Francesco De Lorenzo (ECPC) provides input on PREFER work on methodology, clinical case studies and the recommendations coming out of the project. Professor Francesco De Lorenzo is ECPC’s President and colon cancer survivor. He is medical doctor and professor of biochemistry from the University Federico II Naples. Furthermore, Prof. De Lorenzo has a rich experience in cancer advocacy being the co-founder, former Vice-President and Board member of ECPC. He is also the founder and President of the Italian Association of Cancer Patients (AIMaC), Italy's first Cancer Information Service (CIS), and of the Italian Federation of Cancer Patients Organisations (FAVO). Prof. De Lorenzo is very active in Italy's governmental network of cancer Institutes (ACC), Italy's National Cancer Plan Committee, and the National Volunteer Observatory of the Italian Welfare Ministry. He was previously engaged in Italian politics as a Member of Parliament, holding several ministerial mandates (Ministry of Health, 1989-1993).
Researchers who are doing the work
- Andrea Beyer, Actelion Pharmaceuticals
- Angelo Paradiso, Istituto Tumori of Bari
- Antje Tockhorn, Elli Lilly
- Ardine de Wit, UMC Utrecht
- Axel Hueber, University of Erlangen
- Bas Donkers, Erasmus University Rotterdam
- Bennett Levitan, Janssen
- Cathy Anne Pinto, MSD
- Cecilia Jimenez Moreno, Newcastle University
- Dario Monzani, European Institute of Oncology
- Eline van Overbeeke, Katholieke Universiteit Leuven
- Elisabeth Wood, Newcastle University
- Emily Freeman, Abbvie
- Enrica Capeletto, Istituto Tumori of Bari
- Esther de Bekker-Grob, Erasmus University Medical Centre & Erasmus University Rotterdam
- Eva Katz, Janssen
- Francesco De Lorenzo, European Cancer Patient Coalition
- Georges Quartey, Roche
- Giulia Marton, European Institute of Oncology
- Grainne Gorman, Newcastle University
- Gunnar Schroefel, Bayer
- Gwenda Simons, University of Birmingham
- Hanns Lochmueller, Newcastle University
- Heiko Götte, Merck KGaA
- Ian Smith, UMC Utrecht
- Irina Cleemput, Belgian Health Care Knowledge Centre
- Isabelle Huys, Katholieke Universiteit Leuven
- Jenny Sharpe, Muscular Dystrophy UK
- Jorien Veldwijk, Erasmus University Rotterdam
- Karim Raza, University of Birmingham
- Kimberley Hockley, Amgen
- Kristin Bullok, Elli Lilly
- Laura Vergani, European Institute of Oncology
- Leo Russo, Pfizer
- Luca Bailo, European Institute of Oncology
- Lydia Makaroff, European Cancer Patient Coalition
- Mariam Jamali, Bayer
- Marie Falahee, University of Birmingham
- Matthias Englbrecht, University of Erlangen
- Mazzocco Ketti, European Institute of Oncology
- Meredith Smith, Amgen
- Monika Borchert, Novartis
- Nikoletta Nikolenko, Newcastle University
- Patricia Fleuranceau-Morel, Merck KGaA
- Plamen Kozlovski, Novartis
- Pooja Merchant, Bayer
- Pravin Girase, Roche
- Rachael DiSantostefano, Janssen
- Rosanne Janssens, Katholieke Universiteit Leuven
- Sarah Verschueren, MindBytes
- Stephen Heaton, Bayer
- Stephen Watt, Pfizer
- Ulrik Kihlbom, Uppsala University
- Vaishali Patadia, Sanofi